153 related articles for article (PubMed ID: 8246608)
1. Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line.
Law JC; Ritke MK; Yalowich JC; Leder GH; Ferrell RE
Leuk Res; 1993 Dec; 17(12):1045-50. PubMed ID: 8246608
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques.
Neubauer A; He M; Schmidt CA; Huhn D; Liu ET
Leukemia; 1993 Apr; 7(4):593-600. PubMed ID: 8464238
[TBL] [Abstract][Full Text] [Related]
3. p53 in chronic myeloid leukemia cell lines.
Bi S; Hughes T; Bungey J; Chase A; de Fabritiis P; Goldman JM
Leukemia; 1992 Aug; 6(8):839-42. PubMed ID: 1640738
[TBL] [Abstract][Full Text] [Related]
4. Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells.
Hietanen SH; Kurvinen K; Syrjänen K; Grénman S; Carey T; McClatchey K; Syrjänen S
Am J Obstet Gynecol; 1995 Nov; 173(5):1477-82. PubMed ID: 7503188
[TBL] [Abstract][Full Text] [Related]
5. Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia.
Gaidano G; Serra A; Guerrasio A; Rege-Cambrin G; Mazza U; Saglio G
Ann Hematol; 1994 Jan; 68(1):3-7. PubMed ID: 8110876
[TBL] [Abstract][Full Text] [Related]
6. p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro.
Sen S; Zhou H; Andersson BS; Cork A; Freireich EJ; Stass SA
Cancer Genet Cytogenet; 1995 Jul; 82(1):35-40. PubMed ID: 7627932
[TBL] [Abstract][Full Text] [Related]
7. Mutation of the p53 gene in human acute myelogenous leukemia.
Slingerland JM; Minden MD; Benchimol S
Blood; 1991 Apr; 77(7):1500-7. PubMed ID: 2009369
[TBL] [Abstract][Full Text] [Related]
8. Multiple aberrant splicing of the p53 transcript without genomic mutations around exon-intron junctions in a case of chronic myelogenous leukaemia in blast crisis: a possible novel mechanism of p53 inactivation.
Nakai H; Kaneko H; Horiike S; Ariyama Y; Misawa S; Kashima K; Ishizaki K
Br J Haematol; 1994 Aug; 87(4):839-42. PubMed ID: 7527245
[TBL] [Abstract][Full Text] [Related]
9. [The effect of the tumor suppressor p53 and its mutant forms on the differentiation and viability of K562 leukemic cells].
Kremenetskaia OS; Logacheva NP; Baryshnikov AIu; Chumakov PM; Kopnin BP
Tsitologiia; 1996; 38(12):1280-93. PubMed ID: 9163103
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the p53 gene in patients with isochromosome 17q and Ph1-positive or -negative myeloid leukemia.
Schütte J; Opalka B; Becher R; Bardenheuer W; Szymanski S; Lux A; Seeber S
Leuk Res; 1993 Jun; 17(6):533-9. PubMed ID: 8505851
[TBL] [Abstract][Full Text] [Related]
11. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
Okabe M
Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
[TBL] [Abstract][Full Text] [Related]
12. Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line.
Chow VT; Quek HH; Tock EP
Cancer Lett; 1993 Sep; 73(2-3):141-8. PubMed ID: 8221626
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides.
Lanza F; Bi S; Moretti S; Castoldi G; Goldman JM
Br J Haematol; 1995 May; 90(1):8-14. PubMed ID: 7786800
[TBL] [Abstract][Full Text] [Related]
14. Structural organization of BCR-ABL gene in chronic phase and blast transformation in chronic myeloid leukemia patients.
Martinelli G; Zaccaria A; Farabegoli P; Buzzi M; Testoni N; Bragliani M; Panzica G; Tura S
Leuk Lymphoma; 1993; 11 Suppl 1():51-6. PubMed ID: 8251917
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of a new Ph1-positive chronic myeloid leukemia cell line MC3 with trilineage phenotype and an altered p53 gene.
Okabe M; Kunieda Y; Nakane S; Kurosawa M; Itaya T; Vogler WR; Shoji M; Miyazaki T
Leuk Lymphoma; 1995 Feb; 16(5-6):493-503. PubMed ID: 7787756
[TBL] [Abstract][Full Text] [Related]
16. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
17. Hemizygous expression of the wild-type p53 allele may confer a selective growth advantage before complete inactivation of the p53 gene in the progression of chronic myelogenous leukaemia.
Nakai H; Misawa S; Horiike S; Maekawa T; Kashima K; Ishizaki K
Br J Haematol; 1995 May; 90(1):147-55. PubMed ID: 7786777
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562.
Ehinger M; Nilsson E; Persson AM; Olsson I; Gullberg U
Cell Growth Differ; 1995 Jan; 6(1):9-17. PubMed ID: 7718488
[TBL] [Abstract][Full Text] [Related]
19. The abnormal p53 proteins expressed in CML cell lines are non-functional.
Bi S; Lanza F; Goldman JM
Leukemia; 1993 Nov; 7(11):1840-5. PubMed ID: 8231251
[TBL] [Abstract][Full Text] [Related]
20. Frequent mutation of the p53 gene in human esophageal cancer.
Hollstein MC; Metcalf RA; Welsh JA; Montesano R; Harris CC
Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9958-61. PubMed ID: 2263646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
